Literature DB >> 3297288

Carcinoma of the prostate. Hormonal therapy.

J T Grayhack, T C Keeler, J M Kozlowski.   

Abstract

A selective review of the literature regarding hormonal therapy for patients with carcinoma of the prostate is presented to assess the current status of the following: therapeutic advantages, disadvantages and risks of alternate approaches to hormonal therapy; observations to predict the magnitude and duration of response to therapy; indications for initiating hormone therapy; the short-term and long-term effects of therapy; and role of hormone therapy in patients with recurrent tumor activity after initial hormonal measures.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3297288     DOI： 10.1002/1097-0142(19870801)60:3+<589::aid-cncr2820601526>3.0.co;2-r

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


  10 in total

1.  Protocadherin-PC promotes androgen-independent prostate cancer cell growth.

Authors:  Stephane Terry; Luis Queires; Sixtina Gil-Diez-de-Medina; Min-Wei Chen; Alexandre de la Taille; Yves Allory; Phuong-Lan Tran; Claude C Abbou; Ralph Buttyan; Francis Vacherot
Journal:  Prostate       Date:  2006-07-01       Impact factor: 4.104

2.  Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma.

Authors:  I Leav; K M Lau; J Y Adams; J E McNeal; M E Taplin; J Wang; H Singh; S M Ho
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

3.  Prostate-specific antigen as a marker of adenocarcinoma of prostate.

Authors:  P Kellokumpu-Lehtinen; M Nurmi; P Koskinen; K Irjala
Journal:  Urol Res       Date:  1989

4.  The future in advanced prostate cancer: take your partners or is the last dance for me?

Authors:  David I Quinn
Journal:  Rev Urol       Date:  2004

Review 5.  Androgen receptor gene and hormonal therapy failure of prostate cancer.

Authors:  P Koivisto; M Kolmer; T Visakorpi; O P Kallioniemi
Journal:  Am J Pathol       Date:  1998-01       Impact factor: 4.307

6.  Neurotensin is an autocrine trophic factor stimulated by androgen withdrawal in human prostate cancer.

Authors:  I Sehgal; S Powers; B Huntley; G Powis; M Pittelkow; N J Maihle
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

7.  Effect of oral clodronate on bone pain. A controlled study in patients with metastic prostatic cancer.

Authors:  I Elomaa; T Kylmälä; T Tammela; J Viitanen; J Ottelin; M Ruutu; K Jauhiainen; M Ala-Opas; L Roos; J Seppänen
Journal:  Int Urol Nephrol       Date:  1992       Impact factor: 2.370

Review 8.  Hormonal therapy for stage D cancer of the prostate.

Authors:  M R Gudziak; A Y Smith
Journal:  West J Med       Date:  1994-04

Review 9.  Castration-Resistant Prostate Cancer: Sequencing Oral and Infusion Agents.

Authors:  Sarah Bennett Starosta; Stephen J Savage
Journal:  Curr Urol Rep       Date:  2018-07-20       Impact factor: 2.862

10.  No effect of unacylated ghrelin administration on subcutaneous PC3 xenograft growth or metabolic parameters in a Rag1-/- mouse model of metabolic dysfunction.

Authors:  Michelle L Maugham; Inge Seim; Patrick B Thomas; Gabrielle J Crisp; Esha T Shah; Adrian C Herington; Kristy A Brown; Laura S Gregory; Colleen C Nelson; Penny L Jeffery; Lisa K Chopin
Journal:  PLoS One       Date:  2018-11-20       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.